Apan-CH
Latest Information Update: 22 Aug 2003
Price :
$50 *
At a glance
- Originator Praecis Pharmaceuticals
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 22 Aug 2003 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 18 Mar 2001 Preclinical trials in Alzheimer's disease in USA (unspecified route)